Status:
COMPLETED
Effects of Bashan on Glucose in Type 2 Diabetes Patients and Its Related Mechanisms
Lead Sponsor:
Zhongda Hospital
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The study aimed to observe the effect of targeted diet on blood glucose improvement in type 2 diabetic patients by continuous glucose monitoring and to explore the possible mechanism of targeted diet ...
Detailed Description
Subjects were studied on 2 occasions, separated by at least 7 days, in a randomized fashion. The order of the enteral infusions was randomized and facilitated by a biostatistician who generated the ra...
Eligibility Criteria
Inclusion
- Diagnosed with type 2 diabetes;
- With only diet and exercise control for at least 3 months or stable use of basal insulin for hypoglycemic treatment for at least 3 months;
- Fasting blood glucose is greater than 7.0mmol/L, 2h postprandial blood glucose is greater than 11.1mmol/L, and glycosylated glycoprotein is 7.0-8.5%;
- 18-60 years old;
- Those who have voluntarily signed the informed consent.
Exclusion
- Pregnant or lactating women or women planning pregnancy who are unwilling to take or do not take adequate contraceptive measures;
- Drinking (more than 5 times a week, and 100g liquor or 250g yellow wine or 5 bottles of beer above on average each time) or smoking history;
- Serious mental illness in the past 6 months;
- Those who have undergone gastrointestinal surgery, except appendicitis and hernia surgery;
- Patients with chronic or persistent hepatitis, patients with severe liver disease such as cirrhosis, or those whose hepatitis B surface antigen (HBsAg) is positive and is accompanied by abnormal liver function (serum glutamic pyruvic transaminase and aspartate aminotransferase are 2.5 times the normal value).
- Suffering from Cushing's syndrome, pituitary dysfunction and other endocrine system diseases;
- Factors that hinder participation in the research, such as unstable medical conditions, including blood pressure and cardiovascular disease, etc.
- i. malignant hypertension (blood pressure \> 180/110mmHg, systolic blood pressure \> 180mmHg or diastolic blood pressure \> 110mmHg); unstable blood pressure control; ii. myocardial infarction, other acute cardiac events requiring hospitalization, stroke, transient ischemic attack, or treatment of acute congestive heart failure;
- Suffering from infectious diseases such as tuberculosis and AIDS;
- Anemia: hemoglobin \< 10g/dl;
- Severe renal insufficiency: GFR ≤ 30ml/min/1.73m2;
- Ketosis, ketoacidosis and uncontrolled infection in recent 1 month;
- Those who are deemed unsuitable for participating in this clinical trial by the researcher for any reason;
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05333822
Start Date
March 1 2021
End Date
December 31 2022
Last Update
January 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, Zhongda Hospital. Institute of Diabetes, Southeast University
Nanjing, Jiangsu, China